Chemotherapy-induced cardiotoxicity: importance of early detection

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 12, 2016, Pages 1297-1299

  Cardinale, Daniela ^a   Cipolla, Carlo Maria ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

biomarkers; cancer therapy; cardiac function recovery; Cardiotoxicity; chemotherapy; heart failure; left ventricular dysfunction; left ventricular ejection fraction; prevention; troponin

Indexed keywords

ANTINEOPLASTIC AGENT; TROPONIN;

CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; DOPPLER ECHOCARDIOGRAPHY; EARLY DIAGNOSIS; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN;

EID: 84988969683     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2016.1239528     Document Type: Editorial

References (22)

1. DeSantis C, Lin C, Mariotto A, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2014;64:252–271.
2. Truong J, Yan AT, Cramarossa G, et al. Chemotherapy-induced cardiotoxicity:detection, prevention and management. Can J Cardiol. 2014;30:869–878.• A complete overview on incidence, detection, prevention, management and clinical importance of cardiotoxicity.
3. Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments:epidemiology, detection, and management. CA Cancer J Clin. 2016. doi:10.3322/caac.21341. [Epub ahead of print].
4. Yeh ETH, Bickford CL., Cardiovascular complications of cancer therapy. Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–2247.
5. Tan C, Tasaka H, Yu KP, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20:333–353.
6. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy:a report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–1093.
7. Eidem BW. Identification of anthracycline cardiotoxicity:left ventricular ejection fraction is not enough. J Am Soc Echocardiogr. 2008;21:1290–1292.
8. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy:clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–220.
9. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies:a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2011;13:1–10.
10. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792–3799.
11. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014;32:2159–2165.
12. Lenihan D, Oliva S, Chow E, et al. Cardiac toxicity in cancer survivors. Cancer. 2013;11:2131–2142.
13. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–1988.
14. Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart:a challenge that cardioncology should not miss. Curr Cardiol Rep. 2016;18:51. doi:10.1007/s11886-016-0731-z
15. Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy:a systematic review. J Am Coll Cardiol. 2014;63:2751–2768.
16. Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology. Clin Chem Lab Med. 2011;49:1937–1948.
17. Colombo A, Sandri MT, Salvatici M, et al. Cardiac complications of chemotherapy:role of biomarkers. Curr Treat Options Cardiovasc Med. 2014;16:313.
18. Christenson ES, James T, Agrawal V, et al. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223–235.•• Excellent review on strength and weakness points for the use of various biomarkers in the detection of chemotherapy- induced cardiotoxicity.
19. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high dose chemotherapy. J Am Coll Cardiol. 2000;36:517–522.
20. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–2754.
21. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy:ESMO clinical practice guidelines. Annals of Oncology. 2012;23:vii155–vii166.
22. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–2481.